WCLC 2025 - Posters & ePosters-P3.18.32 Tislelizumab Combined With Bevacizumab and Nab-Paclitaxel as Second-Line Therapy for PD-1/L1 Inhibitor-Resistant Advanced NSCLC

P3.18.32 Tislelizumab Combined With Bevacizumab and Nab-Paclitaxel as Second-Line Therapy for PD-1/L1 Inhibitor-Resistant Advanced NSCLC

Asset Subtitle

Liping Lin

Meta Tag

Speaker Liping Lin

Topic Clinical Trials in Progress